November 3, 2025 — Leads & Copy —
Nuvation Bio Inc. (NYSE: NUVB) reported its Q3 2025 financial results, highlighting the first full quarter of commercial sales for IBTROZI, with 204 new patients receiving the treatment. Founder, President, and CEO David Hung, M.D., noted the team’s expertise in rare diseases and ability to execute.
Key updates include IBTROZI’s median duration of response maturing to 50 months and Nippon Kayaku receiving approval for IBTROZI in Japan, triggering a $25 million milestone payment to Nuvation Bio. The company also enrolled the first patient in a pivotal study for safusidenib and decided against a head-to-head study of safusidenib against vorasidenib.
Financially, Nuvation Bio had $549.0 million in cash, cash equivalents, and marketable securities as of September 30, 2025. Net product revenue from IBTROZI sales in the U.S. was approximately $7.7 million. The company reported a net loss of $55.8 million, or $(0.16) per share, for the quarter.
Nuvation Bio will host a conference call and webcast today at 4:30 pm ET to discuss the results. Details on how to access the call are available on the company’s website.
Contact:
Nuvation Bio
Source: Nuvation Bio
